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Abstract
Background: To allow research organisations to co-ordinate activity to the benefit of national and international
funding strategies requires assessment of the funding landscape; this, in turn, relies on a consistent approach for
comparing expenditure on research. Here, we discuss the impact and benefits of the United Kingdom’s Health
Research Classification System (HRCS) in national landscaping analysis of health research and the pros and cons of
performing large-scale funding analyses.
Methods: The first United Kingdom health research analysis (2004/2005) brought together the 11 largest public
and charity funders of health research to develop the HRCS and use this categorisation to examine United Kingdom
health research. The analysis was revisited in 2009/2010 and again in 2014. The most recent quinquennial analysis in
2014 compiled data from 64 United Kingdom research organisations, accounting for 91% of all public/charitable health
research funding in the United Kingdom. The three analyses summarise the United Kingdom’s health research
expenditure in 2004/2005, 2009/2010 and 2014, and can be used to identify changes in research activity and disease
focus over this 10 year period.
Results: The 2004/2005 analysis provided a baseline for future reporting and evidence for a United Kingdom
Government review that recommended the co-ordination of United Kingdom health research should be strengthened
to accelerate the translation of basic research into clinical and economic benefits. Through the second and third
analyses, we observed strategic prioritisation of certain health research activities and disease areas, with a strong trend
toward increased funding for more translational research, and increases in specific areas such as research on prevention.
Conclusions: The use of HRCS in the United Kingdom to analyse the research landscape has provided benefit both to
individual participatory funders and in coordinating initiatives at a national level. A modest amount of data for each
project is sufficient for a nationwide assessment of health research funding, but achieving coverage of the United
Kingdom portfolio relies on sourcing these details from a large number of individual funding agencies. The effort
needed to compile this data could be minimised if funders routinely shared or published this information in a standard
and accessible way. The United Kingdom approach to landscaping analyses could be readily adapted to suit other
groups or nations, and global availability of research funding data would support better national and international
coordination of health research.
Background
Health research seeks to address some of the most eco-
nomically significant challenges facing society. In the
United Kingdom, the Department of Health (England)
has estimated costs of more than £5 billion per year to
the National Health Service (NHS) [1] and £27 billion
to the economy [2] due to obesity, with almost 1 in 4
adults and around 15% of children being obese [3]. In
2014, the United Kingdom Alzheimer’s Society pub-
lished a major study on the social and economic impact
of dementia in the United Kingdom, which estimated
that there will be 850,000 people living with dementia
in the United Kingdom by 2015 and that dementia
already costs the country £26 billion a year [4].
Therefore, changes to health service delivery and
healthcare, informed by health research, has the poten-
tial to bring substantial economic and wider societal
impacts. In addition, publically-funded health research is
an important attractor for investment from a global,
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research-intensive pharmaceutical industry which in
turn can bring additional associated spill-over benefits
[5]. A recent analysis of the impact case studies submit-
ted via the 2014 United Kingdom Research Excellence
Framework exercise identified £2 billion of health gain
from 11 such impacts alone in the period 2008–2012
[6]. Investment in health research is therefore widely
regarded as generating positive economic returns [7],
but estimations of these returns are often highly
caveated and, indeed, the means to measure such
returns require further development [8].
One challenge to obtaining better estimates of the
benefits from health research is that health research is
supported by a broad range of public and charitable
funders working alongside the pharmaceutical industry,
and thus details about the inputs into the system are
not available in one place. Collaboration between these
sectors are common, but each sector has its own stra-
tegic plans and policies through which funding is
assigned. To co-ordinate activity across funders, with
the aim of maximising impact, knowledge of the fund-
ing landscape (which research activities are funded,
where and by which funder) is needed.
Funding organisations are acutely aware of the bene-
fits of co-ordinating resources and supporting comple-
mentary, rather than competing, research. Enhanced
coordination has the potential to identify new strategic
investment opportunities, by highlighting areas of un-
met need or prior under-investment.
However, providing a coordinated national approach
to health research has three key requirements:
1. A committed partnership between health research
stakeholders that create and oversee cooperative
ventures.
2. A mechanism to determine the nature of health
research funding on a national level which can be
replicated over time.
3. A common classification system to uniformly
identify types of health research being funded across
a highly diverse range of funder types and research
portfolios.
In the United Kingdom, processes have been in
place for the last decade to coordinate health research
on a national scale, to the benefit of the global
research effort. This process was begun in 2004, with
the establishment of the United Kingdom Clinical
Research Collaboration (UKCRC) [9], a partnership
between United Kingdom research funding bodies, the
NHS, Government and other regulatory bodies, the
biomedical industry, and patients. The UKCRC’s core
aim was to “re-engineer the clinical research environ-
ment in the UK, to benefit the public and patients by
improving national health and increasing national
wealth” [9].
Part of this remit included the development and appli-
cation of the Health Research Classification System
(HRCS) [10], a bespoke system to analyse the United
Kingdom’s health research landscape. Over the last
decade, the HRCS has been used consistently within the
United Kingdom, culminating with the publication of
the third quinquennial analysis in August 2015. We are
therefore now presented with the unique opportunity
to show how the development of the HRCS and its ap-
plication within the United Kingdom has influenced
funding policies over the past 10 years. In particular, we
wish to discuss how the collaboration between different
organisations to sharing funding data has changed the
nature of United Kingdom health research, with impli-
cations not just for the future of the country’s science
base but for applications of classification systems as
policy tools on a global scale.
Methods
The Health Research Classification System
In 2004, the UKCRC, via a dedicated secretariat, both
developed the HRCS and conducted the first United
Kingdom-wide analysis. The HRCS is a two-dimensional
coding system, where each award is coded based on
both the disease of focus (‘Health Category’) and type
of research undertaken (‘Research Activity’). Health
Categories are built from the WHO International Classi-
fication of Diseases [11], whilst Research Activities are
developed from the Common Scientific Outline [12], ori-
ginally developed by the United States National Institutes
of Health National Cancer Institute and now in use by the
International Cancer Research Partnership. The combin-
ation of the two coding arms allows a full breadth of
coverage across all types of health research.
Data collection, coding and analysis
The elements of each individual United Kingdom
Health Research Analysis are explained in more detail
within the published reports [13]. Here, we present a
brief summary of each report’s methodology, which
highlights the key details, the developments made and
changes in practice from 2004/2005, through 2009/
2010 and to 2014. Further information is also available
in our Additional file 1: Supplementary methodology.
All three analyses required funders to submit award
data via a common dataset of information consisting of
a small amount of simple award information, namely
basic Principle Investigator (PI) details such as Institute
and Location, award type, amount and duration, along-
side the award title and abstract, required for coding.
The first United Kingdom Health Research Analysis
(2004/2005) [14] brought together the 11 largest United
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Kingdom research organisations providing 9901 awards
to a central database of funders’ research portfolios. The
second analysis (2009/2010) comprised 12 research
organisations providing 11,482 awards and the third ana-
lysis (2014) contained 17,021 awards from 64 research
organisations.
To provide HRCS coding, the UKCRC Secretariat
provided a complete classification check for the first
analysis with each award independently coded twice
(“dual coded”) then reviewed and standardised for in-
clusion in future HRCS training literature. Subsequent
analyses relied on internal staff trained in HRCS to
provide coding for awards, or via the use of dedicated
external independent coders (“contract coders”). The
dual coded quality control (QC) process was absent
from the 2009/2010 analysis, but was replicated in
the 2014 analysis on over 30% of awards.
Results
Analysis results: 2004/2005 to 2014
The original United Kingdom Health Research Ana-
lysis (2004/2005) accounted for £950 million of spend
(£1.19 billion in 2014 real termsa) (Table 1). Segregation
by research activity showed the majority of funding (£816
million, 68.6%) was allocated to basic research types
‘Underpinning’ and ‘Aetiology’. Assessment of health
categories showed ‘Generic Health Relevance’, used to
classify awards relevant to all diseases and conditions
or to general health and well-being, received the most
funding (£300 million, 25%) followed by ‘Cancer’
(£242 million, 20%). The study also compared health
category findings with United Kingdom burden of
disease, via the WHO Disability Adjusted Life Years
(DALYs) 2002 estimates [15], and assessed the geo-
graphical distribution of United Kingdom research
funding. The differences seen in these health category
comparisons over time have been relatively small
versus the shifts in research activity spending (Table 1
and Fig. 1).
The 2004/2005 analysis contributed to a landmark
United Kingdom Government review of health research
spending conducted by Sir David Cooksey in 2006 [16].
This review was intended as a means to advise the
Government on the best design and institutional ar-
rangements for public health funding in the United
Kingdom. Data from the HRCS analysis were key com-
ponents in assessment of the current status of United
Kingdom health research upon which suggestions for
future funding policy could be made.
The key recommendation from the Cooksey Review
was to strengthen translation of research into health
and economic benefits. The Cooksey report noted the
UKCRC analysis showed two thirds of research funding
is invested in basic science, and that, while the
reviewers supported sustained funding in this area, they
recommended “that future increases in funding should
be weighted towards translational and applied research
until a more balanced portfolio is achieved” [16].
Using the 2004/2005 analysis as baseline, the second
United Kingdom Health Research Analysis (2009/2010)
showed that funding for health research from the United
Kingdom public and charity sectors had increased by 50%
in real terms, with £1.77 billion in real terms spend
accounted for. An overall increase in total spend meant
that every research activity saw a real terms increase in
funding, however, the proportion spent on ‘Underpinning’
and ‘Aetiology’ fell (by 6% and 2.9%, respectively) in favour
of increases in the remaining six groups, particularly in
the translational areas of ‘Detection and Diagnosis’
(+2.0%) and ‘Treatment Development’ (+2.1%).
Table 1 Funding distribution by research activity for United Kingdom Health Research Analyses in 2004/2005, 2009/2010 and 2014
HRCS Research Activity
Group
2004/2005 2009/2010 2014 (HRAF) Difference in 2014 (£) Difference in 2014 (%)
Value (£m) % Value (£m) % Value (£m) % vs. 04/05 vs. 09/10 vs. 04/05 vs. 09/10
1 Underpinning 401.7 33.6% 488.7 27.6% 453.5 23.9% 51.8 –35.2 –9.7% –3.7%
2 Aetiology 414.4 34.7% 563.1 31.8% 558.4 29.4% 144. –4.7 –5.2% –2.3%
3 Prevention 29.6 2.5% 66.4 3.7% 101.5 5.4% 71.9 35.2 2.9% 1.6%
4 Detection and Diagnosis 62.9 5.3% 129.9 7.3% 189.0 10.0% 126.1 59.1 4.7% 2.6%
5 Treatment Development 102.9 8.6% 189.3 10.7% 228.8 12.1% 126.0 39.6 3.5% 1.4%
6 Treatment Evaluation 99.0 8.3% 151.5 8.5% 179.0 9.4% 79.9 27.5 1.1% 0.9%
7 Disease Management 27.7 2.3% 57.3 3.2% 71.4 3.8% 43.7 14.1 1.4% 0.5%
8 Health Services 56.2 4.7% 126.1 7.1% 114.9 6.1% 58.7 –11.2 1.4% –1.1%
Grand Total 1194.3 100% 1772.3 100% 1896.5 100% 702.1 124.2 0.0% 0.0%
Note (Table 1 and Figure 1): The 2004/2005 analysis did not include Arthritis Research UK, so data from this charity was added retrospectively in comparisons in the
2009/2010 analysis. The 2014 analysis included contributions from 64 research organisations, however, to allow comparable data with previous analyses, only the Health
Research Analysis Forum (HRAF) group funders (original 11 plus Arthritis Research UK) are included here. Award values are in 2014 real terms, extrapolated from original
spend using GDP deflator data as of December 2014. See the United Kingdom Health Research Analysis 2014 main report for more details
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In addition to assessment of HRCS classifications,
both the 2009/2010 and 2014 reports included an esti-
mation of total United Kingdom expenditure on health-
relevant R&D using sources, such as the United
Kingdom Office for National Statistics data on Gross
Expenditure on Research and Development. The esti-
mation in 2009/2010 was £9.28 billion, with 52% from
the private sector, meaning the £1.77 billion included in
the core analysis constituted approximately 40% of the
total public/charity-funded health research. In compari-
son, the 2014 analysis estimation of total United
Kingdom Health R&D expenditure was £8.5 billion with
48% from the private sector. Therefore, the £3.01
billion compiled for the 2014 analysis constituted
approximately 91% of all public/charity-funded health
research in the United Kingdom.
The third HRCS analysis for 2014 shows some growth
in health research spend, but at a greatly reduced rate;
the Compound Annual Growth Rate (i.e. the mean
annual growth rate), was 4.8% over the 10 years of this
analysis period (2004 to 2014), but was 8.2% in the first
5 years (2004 to 2009) and only 1.4% in the second
5 years (2009 to 2014); substantially lower than the
United Kingdom growth in GDP or growth in the con-
sumer price index, which had a 2% and 2.6% Com-
pound Annual Growth Rate,b respectively, over the
same period. This low real-terms growth in expenditure
over the last 5 years is consistent with data from the
Association of Medical Research Charities in 2010/2011
[17] and 2013/2014 [18], and the United Kingdom Gov-
ernment decision to provide level funding for research
via the research councils in 2010 [19]. In examination
of the research activity distributions, we saw a 5 year
real-terms decrease in funding for ‘Underpinning’ and
‘Aetiology’ (–£35 million and –£4.7 million, respect-
ively), although total spend was still higher in real
terms than in 2004/2005.
The proportion of spend for ‘Underpinning’ and ‘Aeti-
ology’ had also decreased over this second 5 year period
(–3.7% and –2.3%, respectively) meaning an overall
reduction in proportional spending from 69% to 50%
over the full 10 year reporting period. The decreases in
proportional funding to basic research between 2009
and 2014 is counterbalanced with a further increase in
proportional funding for ‘Prevention’ (+1.6%), ‘Detection
and Diagnosis’ (+2.6%) and ‘Treatment Development’
(+1.4%). These changes are displayed in Fig. 1.
Of interest is the contribution that strategic initiatives
have made to specific areas such as prevention research.
Across the 10 year reporting period, ‘Prevention’
research spending more than tripled in real terms (£29
million to £101 million) with twice the proportion of
total spend (2.5% in 2004, 5.4% in 2014). The National
Prevention Research Initiative (NPRI) was launched in
October 2004 as a joint funding capacity building
venture between 14 government departments, research
councils and medical charities to support prevention
research for cancer, diabetes and heart disease via risk
reduction/health behaviour. The initiative has recently
been evaluated by an independent expert review panel
which concluded that the NPRI had successfully
strengthened United Kingdom public health prevention
research [20]. The process consisted of four funding
phases (Fig. 2). Between the first and second UKCRC
analyses, the first two funding calls were active, while
third and fourth call projects would be active in the
2014 UKCRC report. A total of £34 million was commit-
ted to the NPRI over the four calls. However, it is im-
portant to note that this would only account for roughly
half the increase in funding seen between 2004 and
2014. The NPRI therefore represents the major, but
not the exclusive, policy initiative that has built up
the level of prevention research in the United
Kingdom.
Fig. 1 Note (Table 1 and Figure 1): Changes in proportion of research activity spend from the United Kingdom Health Research Analyses 2004–2014
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The increases over the last decade in ‘Detection and
Diagnosis’ and ‘Treatment Development’ suggest that
the initiatives recommended by the Cooksey Review
and the subsequent strategic planning by Office for
Strategic Coordination of Health Research have been
realised. In the 10 year reporting period, both research
activity areas received £126 million more in real terms
spend and increased their share of overall spend by
3.5% and 4.7%, respectively. However, it is important to
note that the Cooksey review focussed on the Govern-
ment funding for health research, principally via the
Medical Research Council and NIHR. Charitable
funders support more than 40% of both ‘Detection and
Diagnosis’ and ‘Treatment Development’ spending.
Indeed, individual funder comparisons show the three
largest United Kingdom charitable funders, British
Heart Foundation, Cancer Research UK and Wellcome
Trust, had the largest proportional gains in these two
research activities. While the Cooksey Review recom-
mended increased collaboration with other research
stakeholders, these stakeholders have also changed their
policies to improve translational research. For example,
the Wellcome Trust’s Innovation Division, established
in 2003, is specifically tasked with promoting transla-
tional health research [21].
Discussion
Further application and development
In addition to the main HRCS analysis series, the
classification system has been applied by other United
Kingdom funders for internal reporting and further
analyses. The full details of the classification system
and data collected for the analyses are freely available
via the HRCS website [10] and have been used exten-
sively [22–26]. The majority of large funders also in-
tegrate HRCS coding into their portfolio management
systems, allowing HRCS to be used for internal assess-
ments and for answering policy questions and/or free-
dom of information requests. Data from HRCS coding
features regularly in the Medical Research Council
annual reports and appear on public award databases,
including the Research Council United Kingdom’s
Gateway to Research [27] and NIHR Evaluation, Trials
and Studies (NETS) project portfolio [28].
In 2011, the European Medical Research Councils
(EMRC, now SRG-MED) and European Science Founda-
tion (ESF) compared a range of research classification
systems, including OECD Frascati, Medical Subject
Headings (MeSH), Australian and New Zealand Stand-
ard Research Classification and United States National
Institutes of Health Research, Condition and Disease
Categorization (RCDC) system [29]. The EMRC and
ESF recommended system was HRCS, with the sugges-
tion for cross-Europe adoption as a portfolio analysis
tool [30], particularly as there was interest in performing
joint European analyses to comment on policies aimed
at development of the European Research Area. The
HRCS has since been trialled or adopted internationally
in Ireland, Sweden, Norway, Switzerland, Canada, Hong
Kong and Singapore.
Classifying award data
Categorisation of research awards is a pre-requisite for
monitoring funding portfolios and allows future plan-
ning of new initiatives and strategies. Fundamental to
any organisation that funds research is the ability to an-
swer questions about what they have funded and where.
As a result of this business need many research organi-
sations use bespoke internal systems to classify award
data. The HRCS could be considered just one example
amongst many classification approaches and, while it
has been successfully implemented in the United
2004/05
Analysis

















Fig. 2 Timeline of National Prevention Research Initiative (NPRI) funding calls and United Kingdom Health Research Analysis reporting periods.
Horizontal Bars indicate the start and end of NPRI funding calls. Bold sections indicate the average start and end dates for awards in each call
period. Vertical Bars show the United Kingdom Clinical Research Collaboration Health Research Classification System Reporting periods (financial
year for 2004/2005 and 2009/2010, calendar year for 2014). Adapted from the Medical Research Council’s NPRI Review 2015 [20]
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Kingdom, its usage and suitability for other organisa-
tions will vary depending on the research foci, funding
organisations and countries involved.
There are, however, two key criteria which gives the
HRCS the potential to become more widely accepted for
health research. Firstly, the HRCS was adapted from
pre-existing, international classification systems (i.e.
International Classification of Diseases 10 & Common
Scientific Outline) to ensure coverage of a full range of
diseases and research activities and to allow alignment
with other systems that use or are based on these
systems (such as WHO Global Burden of Disease DALY
data [31], or NHS England programme spend data [32]).
However, while other classification systems, like MeSH
and RCDC, use extensive medical research thesaurus
terms, HRCS codes were specifically restricted with
the explicit aim to be used at a higher aggregate level
and be more useful for strategic national analysis.
The design of the HRCS as a landscaping tool can
lead to a perception that it lacks granularity. It is true
that a more nuanced method is required to segregate
within HRCS Health Categories; for example, to separate
studies of Alzheimer’s from the overarching HRCS
Health Category of ‘Neurological’. However, the
additional costs in staff time to apply further levels of
coding to a broad landscaping analysis is considerable
and somewhat defeats the purpose of maintaining clas-
sifications at the wider strategic level. Indeed, it is the
principle of universal application with restrained classi-
fication choices that is the greatest strength of the
HRCS, hence the recommendation by the EMRC/ESF
above other comparator classification systems.
Secondly, the HRCS analysis demonstrated that a
small number of data fields for each award (i.e. Title,
Abstract, Start & End Dates, Value, Location) are suffi-
cient for a nationwide assessment of health research
funding and can be successfully implemented by a
diverse collection of research organisations for mutual
benefit. This approach was feasible in practice and could
be used both to monitor the effect of policy changes
within individual organisations and their cumulative
effect on the national funding strategy.
Costs and benefits of health research reporting
Management of the UKCRC exercise depends on a
number of components. Firstly, sufficient resources need
to be available to initiate, manage, and follow-up the
analyses. It is difficult to accurately estimate the full cost
of the three UKCRC analyses as resources have been
contributed across a number of organisations and the
management of the report has changed considerably in
the last 10 years of reporting. The first report (2004/
2005) required substantial support, including significant
time taken to convert grant details held on paper to
electronic records, and a full QC exercise of all coding.
The second report (2009/2010) included more detailed
analysis, such as assessment of investment in infrastruc-
ture and estimation of total United Kingdom health
research expenditure. However, the second analysis did
not include a dedicated project management resource
to co-ordinate work across a large number of funding
agencies, and did not include any dual coding of
awards for QC. The third analysis in 2014 engaged a
part-time project manager, involved more funders,
more awards, a larger proportion of coding was per-
formed internally (rather than contracted out) than
previous analyses, and a third of awards were dual
coded for QC purposes.
However the estimated costs of each exercise (sum-
marised in Table 2), alongside our anecdotal experience
of producing this reporting series, suggests that funder-
led practices will reduce costs over time, but that the
efforts of individual funders benefit considerably from
some dedicated central coordination support. Our
current estimates show that changes in practice over
time could reduce the cost per award to less than one
third of the original analysis.
It is important to note that these project costs, and
the costs associated with changes in funder practices to
establish routine coding, may be somewhat off-set by
the re-use of data for internal reporting, informing on
other funding policies and benchmarking for individual
intra-funder award schemes. The 2014 analysis has
already proven more useful than the 2009/2010 ana-
lysis, simply because it was possible to complete it
sooner after the end of 2014, and so the information
within the report had greater immediate currency. Fur-
thermore, the value of the landscaping reports them-
selves will continue to grow with the full underlying
datasets made freely available for re-use. Despite these
long-term benefits, reduction of costs is an important
consideration for the future of HRCS. One potential
resolution to this issue would be the development of
automated coding, and at the time of writing the com-
pany UberResearch [33] was testing a promising ap-
proach for this. Using computer algorithms to apply
HRCS would clearly reduce the significant human re-
sources needed for routine coding, allowing for larger
and/or more frequent analyses. However, the nuances
of interpreting project descriptions and the language
used to define project aims are likely to continue to re-
quire human input to ensure such algorithms can be
adapted to changes in the language used in abstracts
and developments in research fields. Unsurprisingly, it
is clear that human coders vary in the way that they
apply HRCS categories, despite minimising this vari-
ability through training and guidance. This variation
can be corrected in part by coding awards multiple
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times, the objective of the QC process; however, as
noted above, this adds significantly to the costs of the
exercise. Automated coding has the potential to offer a
consistent and very low cost coding approach, which
could be adapted and retrospectively applied as require-
ments for coding change over time.
Availability of portfolio information
The ability to obtain the necessary data on the awards
funded from a large range of different research organisa-
tions is essential for landscaping analyses. In the past,
the only way to obtain this information was to approach
each funding organisation. Funders are beginning to
provide details of their health research portfolios openly
available in a form that can be systematically re-used at
the award level. Within the United Kingdom, several
funders now make this information publicly available as
a way of accounting for the support they receive from
the public. Yet, many research funders are still hesitant
in making all award information publically available.
It is important to note that details of the studies
supported by the private sector, which constitutes
nearly half the United Kingdom’s health research and
development expenditure, are not available. Due to is-
sues of commercial sensitivity this information is un-
likely to ever be publicly available at the level of
individual projects. Thus, even an established land-
scaping project such as the UKCRC analysis series
capturing 91% of public/charitable funding is still only
representative of half (52%) of national health research
spending [34].
Conclusions
Given the clear benefits of better coordination of health
research, there are efforts being made to compile public
and charity funding information at national and inter-
national levels. International strategic collaborations
such as the Heads of International Research Organisa-
tions [35] and the WHO’s World Health Assembly [36],
aim to promote national, regional and global coordin-
ation of health research. In addition, efforts have
already been made to establish a comprehensive inter-
national dataset of awards such as the WHO global
health research and development observatory [33] and
National Institutes of Health World RePORT system.c
Just as the United Kingdom HRCS health research ana-
lysis has proved highly beneficial, more comprehensive
international databases of funding data would be in-
valuable to funding organisations and researchers work-
ing in the field of health research policy. There may
also be benefits to the wider biomedical research com-
munity. Submitting articles for publication, compiling
online CVs, completing institutional or other records of
output and other administrative activities is time
consuming, therefore having a single national or inter-
national record of ‘who funds what where’ in which
grant/award details can be looked up, selected and
transferred, rather than re-entered, would be of consid-
erable importance.d Similar to DOIs for research papers
and ORCIDs for researchers, a single source of grant
identifiers would support funders and researchers alike
to align the outputs of research with the funding that
supports it.
From our experience with the UKCRC report series,
we believe that funders are increasingly seeing the
benefit to sharing their portfolio data, both to their
individual organisations, and collectively for strategy
development at a national level. Open data from fun-
ders would allow easier benchmarking between research
organisations, easier comparison of research strategies
and maintaining competitiveness. In addition, research
funders could identify potential partner organisations
with similar or complimentary interests, more readily
identify appropriate peer reviewers, and streamline re-
searcher recruitment and funding assessments. Fur-
thermore, shared, comparable award information will
also benefit researchers, providing invaluable data for
‘science of science policy’ research and a key resource
to link research funding with researcher outputs.
Endnotes
aFor comparison purposes, previous analysis figures
are expressed in real terms (i.e. 2014 prices) using the
UK GDP deflator data as at December 2014. Full details of
the calculations can be found in the Methods chapter.
https://www.gov.uk/government/statistics/gdp-deflators-at-
Table 2 Breakdown of estimated costs for United Kingdom Health Research Analysis reporting
Report No. of Awards Dedicated Staff Dedicated Costs





Total Cost per Award
2004/2005 9900 4 £185,600 £6100 £191,700 £19.36
2009/2010 11,500 0 £54,200 £32,500 £86,700 £7.54
2014 17,000 0.5 £42,000 £39,000 £81,000 £4.75
These estimations are based on the known variables/costs including contract coder expenses, dedicated salaries and report design costs. Where costs are not
easily quantified, primarily internal staff time used, we provide estimates based on time for coding (~12 mins per award) required, portfolio extraction time for
each participating funder and time requirements for report construction (data collection and cleaning, analysis and report writing/publication). See Supplementary
Methods for further details. The 2004/2005 & 2009/2010 costs are extrapolated from original spend estimates using GDP deflator data as of December 2014. See
the United Kingdom Health Research Analysis 2014 main report for more details
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market-prices-and-money-gdp-december-2014-quarterly-
national-accounts. Accessed 10 June 2015.
bGDP and CPI data based on CAGR calculations





table-id=1.1, respectively, Accessed 05 Mar 2016.
cWorld RePORT is an illustrative mapping database
system designed by the US National Institutes of Health
(NIH) to facilitate communication and coordination of
biomedical research funded by major government
agencies and philanthropic organizations around the
world. https://worldreport.nih.gov/index.cfm. Accessed
05 Mar 2016.
dServices such as the Europe Pub Med Central
grant finder http://europepmc.org/grantfinder, or the
ÜberWizard for ORCID provided by UberResearch
Ltd. http://www.uberresearch.com/orcid-wizard/ are ex-
amples of the first datasets/processes to address part of
this issue.
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